Santa Rosa medical device maker TriVascular Technologies reported its revenues increased 62 percent in the second quarter.
Sales grew to $7.8 million, up from $4.8 million a year earlier, the company said Wednesday.
“We had a strong second quarter reflecting ongoing momentum in commercializing our innovative Ovation Stent Graft platform,” President and CEO Chris Chavez said in a statement.
The stent graft system repairs abdominal aortic aneurysms, bulges in the aorta that can rupture, causing internal bleeding and death.
TriVascular reported a net loss for the second quarter of $14.6 million, compared to a loss of $12.8 million for a year earlier. That amounted to a loss of 87 cents per share, compared to a loss of $22.33 a year ago before TriVascular’s initial public offering last April.
The company noted that 4,300 patients worldwide have received the Ovation implants.